39 results on '"Döhner, Konstanze"'
Search Results
2. Clinical evaluation of complete remission (CR) with partial hematologic recovery (CRh) in acute myeloid leukemia: a report of 7235 patients from seven cohorts
3. Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients
4. Validation of myeloproliferative neoplasms associated risk factor RDW as predictor of thromboembolic complications in healthy individuals: analysis on 6849 participants of the SHIP-study
5. In vivo kinetics of early, non-random methylome and transcriptome changes induced by DNA-hypomethylating treatment in primary AML blasts
6. Clinicohematologic and molecular response of essential thrombocythemia patients treated with pegylated interferon-α: a multi-center study of the German Study Group-Myeloproliferative Neoplasms (GSG-MPN)
7. Correction: Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients
8. Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial
9. UBTF::ATXN7L3 gene fusion defines novel B cell precursor ALL subtype with CDX2 expression and need for intensified treatment
10. Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results
11. Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial
12. Germline variants drive myelodysplastic syndrome in young adults
13. Activating JAK-mutations confer resistance to FLT3 kinase inhibitors in FLT3-ITD positive AML in vitro and in vivo
14. TET1 promotes growth of T-cell acute lymphoblastic leukemia and can be antagonized via PARP inhibition
15. Frequency of infections in 948 MPN patients: a prospective multicenter patient-reported pilot study
16. MicroRNA-708 is a novel regulator of the Hoxa9 program in myeloid cells
17. Differences in expression and function of LEF1 isoforms in normal versus leukemic hematopoiesis
18. Functional and clinical characterization of the alternatively spliced isoform AML1-ETO9a in adult patients with translocation t(8;21)(q22;q22.1) acute myeloid leukemia (AML)
19. Functional characterization of BRCC3 mutations in acute myeloid leukemia with t(8;21)(q22;q22.1)
20. getITD for FLT3-ITD-based MRD monitoring in AML
21. KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis
22. Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia—results of the AMLSG 11-08 trial
23. Rearrangements involving 11q23.3/KMT2Ain adult AML: mutational landscape and prognostic implications – a HARMONY study
24. Correction: Frequency of infections in 948 MPN patients: a prospective multicenter patient-reported pilot study
25. Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results
26. Activating JAK-mutations confer resistance to FLT3 kinase inhibitors in FLT3-ITD positive AML in vitro and in vivo
27. TET1 promotes growth of T-cell acute lymphoblastic leukemia and can be antagonized via PARP inhibition
28. UBTF::ATXN7L3gene fusion defines novel B cell precursor ALL subtype with CDX2 expression and need for intensified treatment
29. MicroRNA-708 is a novel regulator of the Hoxa9 program in myeloid cells
30. Differences in expression and function of LEF1 isoforms in normal versus leukemic hematopoiesis
31. Functional characterization of BRCC3 mutations in acute myeloid leukemia with t(8;21)(q22;q22.1)
32. Functional and clinical characterization of the alternatively spliced isoform AML1-ETO9a in adult patients with translocation t(8;21)(q22;q22.1) acute myeloid leukemia (AML)
33. Significant association of cutaneous adverse events with hydroxyurea: results from a prospective non-interventional study in BCR-ABL1-negative myeloproliferative neoplasms (MPN) - on behalf of the German Study Group-MPN
34. Functional characterization of BRCC3mutations in acute myeloid leukemia with t(8;21)(q22;q22.1)
35. Functional and clinical characterization of the alternatively spliced isoform AML1-ETO9ain adult patients with translocation t(8;21)(q22;q22.1) acute myeloid leukemia (AML)
36. Publisher Correction: Significant association of cutaneous adverse events with hydroxyurea: results from a prospective non-interventional study in BCR-ABL1-negative myeloproliferative neoplasms (MPN) - on behalf of the German Study Group-MPN
37. getITDfor FLT3-ITD-based MRD monitoring in AML
38. KITD816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis
39. Publisher Correction: Significant association of cutaneous adverse events with hydroxyurea: results from a prospective non-interventional study in BCR-ABL1-negative myeloproliferative neoplasms (MPN) - on behalf of the German Study Group-MPN.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.